



Multipurpose Prevention Technologies for Reproductive Health

Think Tank

Participant Bios

Sharon Achilles, MD, PhD

*Fellow in Reproductive Infectious Disease and Family Planning
University of Pittsburgh/Magee Women's Hospital*

Dr. Achilles served in the Peace Corps in Mauritania, West Africa for two years where she became aware of the reproductive realities faced by most women throughout their lives. Her PhD research focused on developing vaginal microbicides, women controlled topically applied agents to prevent sexually transmitted infections, including HIV, and unintended pregnancies. Dr. Achilles' current research interests lie at the interface between reproductive infectious disease and family planning. She is investigating the impact of contraceptive hormones on the immune cellular environment of the genital tract in women.

Diana Blithe, PhD

*Program Director
National Institute of Child Health and Human Development (NICHD)*

Dr. Blithe serves as the Program Director for the Contraceptive Development Research Centers Program (CDRCP) and the Male Contraceptive Development Program of the NICHD. In addition, she serves as the Project Officer of the CCTN, which conducts clinical trials on new contraceptives for both women and men. She is also a Principal Investigator on a collaborative research and development agreement with HRA Pharma to develop CDB-2914 as a progesterone receptor modulator for contraceptive and therapeutic applications. Dr. Blithe has served on the editorial boards of the Journal of Biological Chemistry and the Archives of Biochemistry and Biophysics. She is a member of The Endocrine Society and currently serves on the editorial board of Endocrine and as an ad hoc reviewer for other journals.

Heather Boonstra

*Senior Public Policy Associate
Guttmacher Institute*

Ms. Boonstra is a Senior Public Policy Associate in the Guttmacher Institute's Washington, DC office and is responsible for promoting the Institute's sexual and reproductive health agenda in federal law and policy. She is a regular contributor to the Institute's policy journal, the Guttmacher Policy Review, and oversees a portfolio of projects on abortion, adolescent sexual and reproductive health and the integration of family planning and HIV services in the United States and globally. Ms. Boonstra came to Guttmacher in 1999, after working with the Reproductive Health Technologies Project and as a consultant with the Center for International Health and Information, Save the Children, and the Pacific Institute for Women's Health.



Martha Brady, MS

Senior Associate

Population Council

Ms. Brady is a Senior Associate working in the Population Council's Poverty, Gender, and Youth and HIV and AIDS programs. For the past two decades, Ms. Brady has participated in crosscutting research and program initiatives in all regions of the developing world. She directs an initiative aimed at building the platform for HIV prevention products for women and participates in the development of the Council's microbicide-access strategy. She also directs the USAID – funded regulatory activity for multipurpose prevention technologies (MPTs). Ms. Brady previously served as Director of the Population Council's Expanding Contraceptive Choice program, a global program aimed at facilitating access and introduction of reproductive health technologies into public and private sector markets and health systems worldwide. She has collaborated on numerous interagency working groups and consortiums and has worked extensively on female-initiated products. Ms. Brady serves in advisory capacity to the Female Health Foundation, Nike Foundation, Right to Play, and MedTex World. She also lectures at Smith College.

Gina Brown, MD

Coordinator for Microbicides Research and Women and Girls Research

National Institutes of Health, Office of AIDS Research

Dr. Brown serves as Coordinator for Microbicides Research and Women and Girls Research in the Office of AIDS Research at the National Institutes of Health. She was formerly an obstetrical specialist at the New York City Department of Health and Mental Hygiene. She was the first Medical Director for Cicatelli Associates Incorporated, a nonprofit organization that provides training and technical assistance in the areas of HIV and women's health to health care providers. As an Assistant Professor of Clinical Obstetrics and Gynecology at the College of Physicians and Surgeons, Columbia University, Dr. Brown was the Women's Health Director of the Women and Children Care Center at Columbia Presbyterian Medical Center. She served as the Chair of the NIH Office of AIDS Research Advisory Council (OARAC) for 2004 and chairs the OARAC Women and Girls working group. She was a member of the New York City HIV Planning Council where she served as Chair of the Health Work Group. She also is a member of the Board of Directors for Iris House: a Center for Women Living with HIV, and is on the National Medical Committee of Planned Parenthood Federation of America.

Elizabeth Bukusi, MBChB, PhD, MPH

Director, FACES

Center for Microbiology Research, KEMRI

Dr. Bukusi is a Senior Research Officer at the Kenya Medical Research Institute. She also holds an honorary faculty appointment in the Department of Obstetrics and Gynaecology at the University of Nairobi, and a professional research position with the University of Washington Department of Obstetrics and Gynecology. She has worked in clinical research since 1995 and has been the Site Principal Investigator for a number of clinical studies including current studies on pre-exposure prophylaxis of among HIV discordant couples, and Phase I Dapivarine microbicide trials, studies on integration of HIV care services into both family planning and ante natal care and work on gender based violence.

Ward Cates Jr, MD, MPH

*President of Research
FHI*

Dr. Cates joined FHI in 1994 after a 20-year tenure at the CDC where he served in various posts, including Chief of Abortion Surveillance Branch in the Family Planning Evaluation Division, Director of STD/HIV Prevention and Director of the Division of Training, Epidemiology Program Office. Since joining FHI, he has overseen the organization's robust program in HIV prevention research. Dr. Cates led FHI's efforts in supporting last year's groundbreaking CAPRISA 004 trial of tenofovir gel, funded by USAID. Currently, he is Principal Investigator on FHI's USAID-funded grant focused on reproductive health and HIV/AIDS. He has been the PI on the NIH funded HIV Prevention Trials Network from 1995-2006, and the Bill and Melinda Gates Foundation funded West Africa trial evaluating oral tenofovir for HIV prevention. Dr. Cates is an adjunct professor of epidemiology at the University of North Carolina's and Emory University's School of Public Health. He has authored or co-authored more than 450 scientific publications, including 170 original contributions.

Carolyn Deal, PhD

*Chief of Sexually Transmitted Infections Branch
National Institute of Allergy and Infectious Diseases*

Dr. Deal, a microbiologist, is the Branch Chief of the Sexually Transmitted Diseases Branch in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases in the National Institutes of Health. Prior to joining NIAID, Dr. Deal was at the Food and Drug Administration, where she served as Deputy Director for the Division of Bacterial, Parasitic, and Allergenic Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research.

Brid Devlin, PhD

*Executive Vice President for Product Development
International Partnership for Microbicides (IPM)*

Currently responsible for drug development projects at IPM, Dr. Devlin previously served as IPM's Director of Formulation Technology, directing formulation and manufacturing sciences of vaginal rings, gels and films. Before joining IPM, Dr. Devlin was Assistant Director and Group Leader of the Pharmaceutical Sciences Department at Sanofi-Aventis and Senior Manager and head of Pharmaceutical Sciences, Packaging, and Clinical Supplies at Dermik Laboratories, a division of Sanofi-Aventis. In those roles, Dr. Devlin was responsible for directing formulation development of solid and semi-solid dosage forms for global markets, and for packaging development of therapeutic compounds. Dr. Devlin also served as Research Group Leader at Biosyn Inc., and as a Research Associate at McNeil Consumer Healthcare.

Gustavo Doncel, MD PhD

*Deputy Director, Preclinical Research
CONRAD/Eastern Virginia Medical*

Dr. Doncel serves as Deputy Director of CONRAD's preclinical research program and is also the head of the Microbicide and Contraceptive Research Laboratory and a Professor in the Department of Obstetrics and Gynecology at Eastern Virginia Medical School. Dr. Doncel is an internationally renowned expert in anti-HIV microbicial contraceptives. He is MPT Think Tank Participant Bios



a member of advisory boards for various international organizations focused on reproductive health and microbicide development, and is a reviewer for the National Institutes of Health and the World Health Organization. His numerous publications cover various aspects of reproductive biology and medicine such as HIV/AIDS prevention, infertility, and contraception.

Cindra Feuer

Communications and Policy Advisor
AVAC

Ms. Feuer is the Communications and Policy Advisor and helps publish AVAC materials such as the Px Wire Newsletter and the Anticipating Results report series, and works on AVAC's various community education and outreach programs. She has been reporting and writing on HIV/AIDS and its attendant issues for over a decade. Previously, she was Managing Editor at POZ magazine and staff writer for HIV Plus magazine, covering the pandemic both domestically and internationally. As a consultant, Ms. Feuer produced materials for many NGOs and advocacy organizations, including the Treatment Action Group, amfAR, and the International Rectal Microbicide Working Group. Her work in the AIDS movement began as a Case Manager and Community Organizer at Housing Works, the world's largest AIDS housing service.

Polly Harrison, PhD

Senior Advisor
AVAC/IMPT

Dr. Harrison supports AVAC's work in monitoring the prevention research field, guides content and regular communication about field events and needs, and advises on a range of critical policy matters. She serves the Initiative for Multipurpose Prevention Technology similarly, with emphasis on the structure and focus of the scientific agenda framing the Initiative. After nine years leading international health programs at the Institute of Medicine, in 1998 Dr. Harrison founded the Alliance for Microbicide Development, which she directed until 2010 and, in 2004, was selected as a Policy Leader in the "Scientific American 50", its prestigious annual recognition of outstanding leadership in science and technology.

Monica Kerrigan

Senior Program Officer
Bill & Melinda Gates Foundation

Ms. Kerrigan is Senior Program Officer on the Reproductive Health team of the Gates Foundation. Prior to joining the Gates Foundation, she was a Project Officer focused on Maternal and Child Health with UNICEF in Indonesia. Ms. Kerrigan has held several positions with USAID, including Senior Technical Advisor for Reproductive Health, also in Indonesia, where she managed a significant family planning and reproductive health portfolio. She also served as a Contraceptive and Condom Security Advisor with USAID in Washington, DC and as Deputy Chief of the USAID's Communications, Management and Training Division, where she provided technical and strategic guidance to major communication and behavior change programs which reached countries on a variety of health services, including maternal health and family planning. Previously, Ms. Kerrigan directed the Africa office at the Johns Hopkins University Program for International Education in Reproductive Health and served as a Peace Corps volunteer in a rural primary health care setting in Mali.

Laurel Lagenauer, PhD

Senior Scientist

Osel Inc.

Dr. Lagenauer is a Senior Scientist at Osel, and was the PI for SBIR Phase I grant in support of the development of the MucoCept HIV approach. Dr. Lagenauer is a molecular biologist, with experience in virology and bacteriology. She completed a three-year postdoctoral fellowship in the Department of Stomatology at the University of California, San Francisco where she studied the pathogenesis of Epstein Barr Virus in HIV disease. In addition, prior to her graduate studies, Dr. Lagenauer has seven years of experience as a clinical microbiologist in both human and veterinary fields.

Judy Manning, PhD

Health Development Officer

United States Agency for International Development

Dr. Manning is a Health Development Officer for the Office of Population and Reproductive Health, US Agency for International Development (USAID). She holds a doctoral degree in zoology and completed postdoctoral training in reproductive sciences. She previously served as a Senior Biomedical Research Advisor and Technical Advisor at USAID. She has also worked with the American Association for the Advancement of Science, and the Smithsonian Institution's National Zoological Park in Washington, DC. In her current position at USAID, Dr. Manning is primarily involved with the research and development of female controlled methods that protect women against both pregnancy and HIV/STIs.

Jeff Meer

Special Advisor, Global Health Policy and Development

The Public Health Institute

Mr. Meer is Special Advisor for Global Health Policy and Development at the Public Health Institute (PHI). He is also a Steering Committee Member of the Global Health Technologies Coalition, representing PHI. Based in Washington, DC, he provides strategic guidance to PHI on global health advocacy and develops new business proposals for global health projects. Prior to this, he had been Director of International Advocacy for the Planned Parenthood Federation of America, and was Executive Director of the US Association for UNHCR, a private nonprofit that builds financial and political support for the United Nations Refugee Agency as well as founding Program Officer for Peace and Security at the UN Foundation. Mr. Meer was a Foreign Service Officer with the US Department of State for more than a decade, serving overseas in the People's Republic of China and in Germany, as well as in Washington. During this time, he was a staff delegate to the UN Fourth World Conference on Women in Beijing.

Michael Miller, PhD

Senior Director of Clinical Virology

Gilead Sciences

Dr. Miller is the Senior Director of Clinical Virology at Gilead Sciences, Inc. His responsibilities include overseeing the resistance analyses associated with the development of Gilead's antiviral drugs to HIV, HBV and HCV. His research interests include defining the molecular mechanisms of resistance to antiviral drugs and the clinical effects of drug resistance among different antiviral compounds and mutation patterns. Prior to joining Gilead Sciences, Dr. Miller completed a postdoctoral fellowship in Virology at the Gladstone Institute in San Francisco.

Charu Mullick, MD

Medical Officer

Food and Drug Administration

Dr. Mullick is a Medical Officer in the Division of Antiviral Products at the Food and Drug Administration. She has served in the Division of Antiviral Products as a clinical reviewer since 2007. In 2005, she served in NIH National Institute of Allergy and Infectious Diseases as a physician including involvement in international clinical trials. Currently, she is a clinical reviewer responsible for the development of new products for the treatment and prevention of HIV infection, herpes infections, hepatitis C, influenza and other emerging viral infections. Dr. Mullick is also the lead Medical Officer for microbicide products for HIV prevention. She has participated in several microbicide workshops and meetings.

Naomi Rutenberg, PhD

Vice President, HIV & AIDS Program

Population Council

Dr. Rutenberg, Vice President and Director of the Population Council's HIV and AIDS program, has participated in behavioral and program research on HIV and AIDS and reproductive health for more than two decades. She has been a Principal or Co investigator on a number of research studies of operational strategies for the prevention of mother-to-child transmission of HIV, adolescent pregnancy and HIV risk in South Africa, integrated HIV and reproductive health care in Uganda, HIV prevention and care programs for health workers in Zambia, and the impact of HIV on youth in South Africa. Dr. Rutenberg is currently collaborating on research examining interventions to meet the reproductive health needs of HIV positive women, strengthening HIV care for pregnant women, and addressing operational challenges to diagnosing and managing pediatric HIV infection.

Jeff Roberts, MD

Medical Officer

Food and Drug Administration

After residency, Dr. Roberts joined Dr. John Schiller's lab at NIH to pursue an interest in HPV virology. In the lab, Dr. Roberts helped develop a mouse model for cervicovaginal HPV infection. He used the model to investigate the pathophysiology of the early events of HPV infection in vivo and to characterize the effects of topical contraceptives (e.g., nonoxynol-9) and candidate microbicides (e.g., carrageenan) on genital transmission of HPV. He also applied the model to nonhuman primates to explore the possible impact of cytology screening on HPV infection. In 2008, Dr. Roberts joined FDA's Office of Vaccines, where he analyzes the clinical data on vaccines in all phases of development. He evaluates a wide variety of vaccines, but his primary interest continues to be in vaccines that target sexually transmitted infections, particularly HPV and HSV.

Joseph Romano, PhD

President, NWJ Group LLC

MTN Consultant

Dr. Romano is currently President of NWJ Group, LLC, and serves as a consultant to the HIV prevention field. Previously, he was Chief and Executive Director of Product Development at IPM, where he led the development of a number of microbicide products including dapivirine vaginal ring and gel, maraviroc combination products, and other earlier stage MPT Think Tank Participant Bios

compounds. Before joining IPM, he was Vice President of Research at Biosyn, a small biotech company that was focused on women's health products, including microbicides and contraceptives. Prior to this, Dr. Romano worked for 10 years in an AKZO-Nobel subsidiary, Organon-Tekinca, where he was involved in various HIV research and development projects including HIV pathology, immune response characterization, vaccines, and diagnostic technology development.

John Schiller, PhD

Head, Neoplastic Disease Section

National Cancer Institute

Dr. Schiller, a molecular biologist, joined the Laboratory of Cellular Oncology as a National Research Service Award Postdoctoral Fellow in 1983. Dr. Schiller became a Senior Staff Fellow in the LCO in 1986 and assumed his current position of Senior Investigator in 1992. In 1998, he became Chief of the Neoplastic Disease Section of the lab. Dr. Schiller's research has focused on Papillomaviruses (PVs) and a major goal of his laboratory has been to elucidate the role of certain human (H) PVs in the genesis of human cancers and to develop safe and effective vaccines to prevent genital HPV induced disease.

Wayne Shields

President and CEO

Association of Reproductive Health Professionals

Mr. Shields is the President and Chief Executive Officer of the Association of Reproductive Health Professionals (ARHP). He has guided the development and implementation of health education initiatives, scientific programs, and policy activities for ARHP since 1991. He serves on the editorial boards of *Contraceptive Technology Update* and *Clinical Proceedings in Reproductive Health*, the board of the National Cervical Cancer Coalition, and the advisory boards of the International Consortium for Emergency Contraception and the American Society for Emergency Contraception.

Alan Stone, BSc, DPhil

Director

MEDSA Ltd.

Dr. Stone trained as a biochemist and molecular biologist. He currently serves as Senior International Development Consultant to the Initiative for Multipurpose Prevention Technologies (IMPT), helping strengthen the Initiative globally by bringing strategic stakeholders from diverse spheres (research, government, academia, advocacy and funding) to the effort. From 1990 to 1996 he was Head of the UK Medical Research Council's AIDS Research Management group and in 1991 initiated a new multidisciplinary research program on microbicides to prevent the sexual transmission of HIV. Since 1996 he has been an independent advisor on numerous international projects concerned with the biomedical prevention of HIV/AIDS. He was a founding member of the International Working Group on Microbicides, established by WHO to facilitate this aim, and from 2000 to 2008 served as its Chairman. Dr. Stone is a trustee of the Medical Research Foundation, the registered charity of the UK Medical Research Council.

Jim A. Turpin, PhD

*Microbiologist, Prevention Sciences Branch, Division of AIDS
National Institute of Allergy and Infectious Diseases*

Dr. Turpin is a Program Officer and Preclinical Team leader in the Prevention Sciences Program of the Microbicide Research Branch in the Division of AIDS (DAIDS) in the National Institute of Allergy and Infectious Disease (NIAID) at the National Institutes of Health (NIH). His responsibilities include oversight and management of the microbicide preclinical program. He is the Program Officer and contact for the HIV topical microbicide development programs: Integrated Preclinical/Clinical Program for HIV Topical Microbicides (IPCP-HTM) and the Microbicide (R21/R33) Innovation Program (MIP). Dr. Turpin is also involved with the Comprehensive Resources for Topical Microbicide and Biomedical Prevention (CRMP) contract, which provides gapfilling resources for topical microbicide and prevention development.

Richard Walker, PhD

*Director, Enteric Vaccine Initiative
PATH Vaccines*

Dr. Walker is the Director of the PATH project, the Enteric Vaccine Initiative. He has over 25 years of experience in vaccine development at the Naval Medical Research Institute, where he directed the enteric diseases program; the Armed Forces Radiobiology Research Institute; and Antex Biologics, Inc. For the past seven years, Dr. Walker has served as Director of the Division of Bacterial, Parasitic, and Allergenic Products at the US Food and Drug Administration.

Kevin Whaley, PhD

*CEO
Mapp Biopharmaceutical*

Dr. Whaley has worked on the development of microbicides and contraceptives for the last 30 years. As co-founder of ReProtect LLC., Dr. Whaley helped develop BufferGel and Duet from concept through advanced clinical trials. In parallel, as co-founder Mapp Biopharmaceutical, he is developing antibody based microbicides, therapeutics, and mucosal vaccines that are appropriate for large, cost sensitive, global health markets. He was also a co-founder of the Alliance for Microbicide Development and the Coalition Advancing Multipurpose Innovations.

Charles Wira, PhD

*Professor of Physiology and Neurobiology
Dartmouth Medical School*

Dr. Wira's research focuses on how female sex hormones influence immunity in the female reproductive tract using animal models and human tissues. As PI of an NIH funded Program Project grants for the past 14 years, Dr. Wira heads a major collaborative effort at Dartmouth Medical School to characterize immune functions in the Fallopian tube, uterus, cervix and vagina and to define the roles of sex hormones in mucosal immune regulation. He is actively involved in a grant that is working with colleagues at Dartmouth and the University of Muhimbili in Tanzania to bring scientists to Dartmouth for training in HIV related Mucosal Immunology. He also sits on the board of directors of an NGO at the University of Nairobi, Kenya that focuses on improving women's health against a spectrum of diseases, including AIDS. He is the past Secretary to American Society of Reproductive Immunology, and has served as Councilor for ASRI from 1998 to 2006. Dr. Wira is presently the Secretary General of ISIR and the President Elect of ASRI (2008-2009). Most recently, he received a five year NIH grant to understand the role that human FRT immune cells play in protection

MPT Think Tank
Participant Bios



against the heterosexual transmission of HIV-1. These studies will be carried out in the USA and with colleagues in Muhimbili College of Health Sciences (MUCHS) in Dar es Salaam, Tanzania.

Bethany Young Holt, PhD, MPH

Director

CAMI/Public Health Institute, UC Berkeley

Dr. Young Holt is a PI with the Public Health Institute and is on the faculty of the University of California at Berkeley School of Public Health. An epidemiologist, she directs the Coalition Advancing Multipurpose Innovations (CAMI), a consortium of biotech developers, researchers, health advocates, and clinicians working in the area of reproductive health. CAMI serves as the Secretariat for the Initiative for Multipurpose Technologies (IMPT), a global health initiative that raises awareness about and support for new technologies that can be used to address multiple reproductive health needs. Her research includes market, acceptability and cost effectiveness studies of microbicides. Dr. Young Holt has more than 20 years of experience working in reproductive health and HIV/STI prevention in the US and internationally, including traineeships at the National Cancer Institute, the Centers for Disease Control and Prevention, and the Institute Pasteur in Dakar, Senegal; Peace Corps volunteer work in Mauritania, West Africa; and relief work with the U.N. High Commission for Refugees (UNHCR) in Senegal and Ethiopia.

Rapporteur: Anke Hemmerling, MD, PhD, MPH

Project Director, UCSF Bixby Center

CAMI Steering member

Dr. Hemmerling has been a Project Director at the UCSF Bixby Center for Global Reproductive Health since 2007, implementing clinical trials to study probiotics for the prevention of genital infections. During medical school and residency in Obstetrics & Gynecology she worked in health projects and hospitals throughout Latin America. From 2004 to 2007, she worked as a postgraduate research fellow for the Bixby Program at the UC Berkeley School of Public Health and as a Director of Special Health Projects for Venture Strategies for Health and Development, being involved in a number of global women's health projects.